Day trading IdeaPlease note:
- I'm just sharing my view. its not a recommendation for buying or selling.
- penny stocks moves most of the times are " pump n dump". don't chase them, and you must have an exit plan.
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−7.63 M USD
743.00 K USD
About CAN FITE BIO
Sector
CEO
Motti Farbstein
Headquarters
Ramat Gan
Website
Founded
1994
FIGI
BBG003CMFDM2
Can-Fite BioPharma Ltd. is a biopharmaceutical company, which engages in the development of drugs for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. Its product pipeline include Piclidenoson, Namodenoson, and CF602. The company was founded by Pnina Fishman and Ilan Cohn on September 11, 1994 and is headquartered in Petach-Tikva, Israel.
CANF: Another small biopharma to consider.UP strongly on big volume today on very positive news.
Expect volatility. High risk.
Process your way.
$CANF ready for breakout? 12rr ideaif next 15m candle closes above 3.22 will be bullish on it
Now or never, This is a key level. Gap will fill if trendline rejects. need a close above 3.22
$CANF Signs $42.7 Million Out-Licensing Deal with EwopharmaCan-Fite Signs $42.7 Million Out-Licensing Deal with Ewopharma
Swiss Ewopharma to market Piclidenoson and Namodenoson in Central Eastern Europe (CEE)
$2.25 million upfront payment with an additional $40.45 million for regulatory & sales milestones and 17.5% royalties are included
finance.yahoo.co
$CANF Can Fite Biopharma Long Into earnings Potential trade into earnings with top of channel as a longer term target.
Golden cross imminent
$CANF Can-Fite BioPharma Ltd. 20% upside Can-Fite BioPharma Ltd. engages in the development of drugs for cancer and inflammatory diseases. The company was founded by Pnina Fishman and Ilan Cohn on September 11, 1994 and is headquartered in Petach-Tikva, Israel.
CAN FITE BIOPHARMA reports positive data from Phase-II study of CAN FITE BIOPHARMA (NYSE:CANF) proliferated 11.24% since last week. The company, on June 30 announced its final data analysis of the NASH study, which is in Phase-II. The company announced that it observed positive data, where there was sustained reduction and highly efficient too, in the volume of
See all ideas
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.